Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of the American Academy of Dermatology

Topics

Medicine

Pathology

Physiology

Dermatology

Internal Medicine

Show all topics

DOI

10.1016/j.jaad.2018.01.017

License

CC-BY-NC-ND

Other Formats

PDF